NextCell Pharma AB (STO:NXTCL)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.266
-0.060 (-4.52%)
Mar 9, 2026, 5:14 PM CET
-64.24%
Market Cap 147.71M
Revenue (ttm) 9.83M
Net Income (ttm) -38.79M
Shares Out 111.39M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 195,101
Average Volume 287,942
Open 1.310
Previous Close 1.326
Day's Range 1.250 - 1.310
52-Week Range 0.630 - 3.600
Beta 0.72
RSI 46.86
Earnings Date May 28, 2026

About NextCell Pharma AB

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 24
Stock Exchange Nasdaq Stockholm
Ticker Symbol NXTCL
Full Company Profile

Financial Performance

In fiscal year 2025, NextCell Pharma AB's revenue was 11.06 million, a decrease of -1.90% compared to the previous year's 11.28 million. Losses were -35.14 million, -16.25% less than in 2024.

Financial Statements

News

There is no news available yet.